Torge Rempe, MD, PhD, University of Florida College of Medicine, Gainesville, FL, highlights the unpredictable nature of myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD), which can manifest either as a relapsing or monophasic disease. Data from their study revealed that two-thirds of patients experienced a relapsing course, with 19% encountering their first relapse five years or more after their initial episode. This emphasizes the potential underestimation of relapse rates in current estimates. The challenge lies in determining which patients will experience subsequent relapses, as initiating long-term immunotherapy might be unnecessary for those with a monophasic course. Identifying those at higher risk could lead to earlier intervention with immunotherapy, potentially preventing further relapses. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.